Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives

被引：31

作者：

Natsuaki, Masahiro ^{[1
]}

Sonoda, Shinjo ^{[1
]}

Yoshioka, Goro ^{[1
]}

Hongo, Hiroshi ^{[1
]}

Kaneko, Tetsuya ^{[1
]}

Kashiyama, Kuninobu ^{[1
]}

Yokoi, Kensuke ^{[1
]}

Hikichi, Yutaka ^{[2
]}

Node, Koichi ^{[1
]}

机构：

[1] Saga Univ Hosp, Dept Cardiovasc Med, 5-1-1 Nabeshima, Saga 8498501, Japan

[2] Saga Med Ctr, Cardiovasc Ctr, Koseikan, Saga, Japan

来源：

CARDIOVASCULAR INTERVENTION AND THERAPEUTICS | 2022年 / 37卷 / 02期

关键词：

Antiplatelet therapy; Antithrombotic therapy; Percutaneous coronary intervention; ELUTING STENT IMPLANTATION; ARTERY-DISEASE; CARDIOVASCULAR EVENTS; ATRIAL-FIBRILLATION; OPTIMAL DURATION; VASCULAR EVENTS; FOCUSED UPDATE; DOUBLE-BLIND; CLOPIDOGREL; ASPIRIN;

D O I：

10.1007/s12928-022-00847-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Antiplatelet therapy after percutaneous coronary intervention (PCI) has been changing in parallel with the development of drug-eluting stents (DES) and antiplatelet agents. The recommendation of dual antiplatelet therapy duration is getting shorter due to the decreased risk of stent thrombosis in new-generation DES, the use of a P2Y(12) inhibitor as a monotherapy, and the increasing prevalence of high bleeding risk patients. Antithrombotic therapy after PCI has also changed due to the introduction of direct oral anticoagulants. Aspirin-free P2Y(12) inhibitor monotherapy is now being evaluated in several prospective studies as a novel strategy of antiplatelet therapy after PCI. This review shows a current status and provides future perspectives for the antiplatelet therapy after PCI.

引用

页码：255 / 263

页数：9

共 50 条

[21] Limitation of antiplatelet therapy after percutaneous coronary intervention
Nomura, Shosaku
Inami, Norihito
Kimura, Yutaka
Urase, Fumiaki
Maeda, Yasuhiro
Iwasaka, Toshiji
PLATELETS, 2008, 19 (05) : 392 - 393
[22] CURRENT STATUS AND FUTURE DIRECTIONS IN ANTIPLATELET THERAPY
Krakat, J.
Mousa, S.
Root, R.
Mousa, S. S.
DRUGS OF THE FUTURE, 2009, 34 (01) : 27 - 41
[23] Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials
Lin, Yaowang
Cai, Zhigang
Dong, Shaohong
Liu, Huadong
Pang, Xinli
Chen, Qiuling
Yuan, Jie
Geng, Qingshan
FRONTIERS IN PHARMACOLOGY, 2022, 13
[24] Antiplatelet Therapy for Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Fioretti, Vincenzo
Sperandeo, Luca
Gerardi, Donato
Di Fazio, Aldo
Stabile, Eugenio
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (14)
[25] Efficacy and safety of triple-antiplatelet therapy after percutaneous coronary intervention: a meta-analysis
Zhang Yong
Tang Hai-qin
Li Jin
Fu Zhao-xin
CHINESE MEDICAL JOURNAL, 2013, 126 (09) : 1750 - 1754
[26] The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent
Hu, Mengjin
Gao, Xiaojin
Yang, Jingang
Yang, Yuejin
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (15)
[27] Dual antiplatelet therapy after percutaneous coronary intervention: Personalize the duration
Howard, Travis M.
Khot, Umesh N.
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2021, 88 (06) : 325 - 332
[28] Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention
Faxon, David P.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2012, 79 (02) : 181 - 197
[29] Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives
Alexopoulos, Dimitrios
Pappas, Christos
Sfantou, Danai
Lekakis, John
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 23 (01) : 13 - 22
[30] Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents
Wong, Yee W.
Prakash, Roshan
Chew, Derek P.
CURRENT OPINION IN CARDIOLOGY, 2010, 25 (04) : 305 - 311

← 1 2 3 4 5 →